Reduction of Bladder Injection Pain With Belladonna Opiate Suppository

• Status: Completed
• Trial end date: 2017-06-26
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to test whether using belladonna & opiate suppositories (B&Os) can improve patient discomfort during Onabotulinumtoxin A (BoNT) injection into the bladder for treatment of overactive bladder, neurogenic detrusor overactivity, or interstitial cystitis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Edgar LeClaire, MD
• Treatments: abobotulinumtoxinA; Botulinum Toxins, Type A; incobotulinumtoxinA; Morphine; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Met clinical criteria under outside care or during the Principal Investigator's routine standard of care for BoNT injection therapy

• No contraindication to BoNT therapy as outlined by drug manufacturer guidelines

• Participants have elected to have the BoNT injection therapy prior to being offered enrollment into the study for either overactive bladder (OAB), neurogenic detrusor overactivity (NDO), or refractory interstitial cystitis (IC)

Exclusion Criteria:

• Currently pregnant

• Currently nursing a baby

• Anticipated geographic relocation within the first 3 months following treatment

• Allergy to morphine, belladonna, or opiates

• Patients will be excluded if participating in another research study

• Individuals unable to provide informed consent or to complete two-week follow-up bladder testing (post-void residual) or data collection will also be excluded